Key result
A 2-year-old girl with acute pancreatitis and lipemia was found to be a compound heterozygote for two novel lipoprotein lipase mutations and remained asymptomatic on a low-fat diet at 12 months.
Case Report (n=1)
Identifies two novel LPL mutations (c.88+2insT and p.P214S) causing severe hypertriglyceridemia and acute pancreatitis in a toddler, which was successfully managed with a strict low-fat diet.
Answers are grounded in this paper and cite their sources.
May support low-fat diet in rare pediatric LPL deficiency; extends mutation spectrum but remains hypothesis-generating.
The diagnosis of acute pancreatitis in young children is often delayed because it is a relatively uncommon cause of gastrointestinal complaint. It can, however, result in significant morbidity and occasional mortality in the pediatric population. A primary cause of pancreatitis is frequently found in young children with the most common aetiologies being blunt trauma, drugs, viral infections, periampullary obstruction, systemic illnesses, and genetic predispositions (1). We report a case of a 2-year-old girl with acute pancreatitis in whom the observation of lipemia led to the discovery of 2 novel mutations in the lipoprotein lipase (LPL) gene. CASE REPORT A 2-year-old East Indian girl presented with a 1-month history of intermittent abdominal pain and vomiting. She presented to the emergency department with her fourth episode of abdominal pain characterised by sudden onset and recurrent vomiting. The pain was severe and poorly localised with no evident exacerbating factors. The episodes of abdominal pain lasted a few hours during which she was unable to tolerate any oral diet. Between episodes of pain, she was asymptomatic. She was born in India to nonconsanguineous parents and immigrated to Australia at the age of 1 year. She had no significant medical or family history. Examination revealed a thriving girl (25th percentile for weight and height) in obvious pain with rebound tenderness in the right iliac fossa on palpation suggestive of acute appendicitis. Laboratory investigations showed a moderate leucocytosis of 17.4 × 109 cells/L (predominately neutrophils). Other laboratory investigations were unremarkable, including urea, creatinine, liver enzymes (alanine aminotranferase, γ-glutamyl transpeptidase, and alkaline phosphatase), serum calcium, and C-reactive protein. An abdominal ultrasound was suboptimal secondary to abdominal tenderness but a moderate amount of free intraperitoneal fluid, hyperaemic appendix, and a “bulky” pancreas were noted. The patient was admitted with a provisional diagnosis of acute appendicitis. The following day, a plasma lipase of 2830 U/L (normal range 0–60 U/L) was reported from the initial blood sample. Repeat abdominal ultrasound revealed a markedly enlarged pancreas with no obvious focal pancreatic or biliary lesions and a normal-appearing appendix. A diagnosis of acute pancreatitis was made and managed with nil by mouth, intravenous fluids, and morphine as required. Antioxidant therapy with vitamins E and C and selenium was commenced. The initial plasma sample was noted on day 2 by the pathologist to have a lipemic appearance (Fig. 1). A lipid profile revealed a triglyceride concentration of 115 mmol/L (normal <1.7 mmol/L). Forty-eight hours after admission whilst fasting, her triglyceride concentration fell dramatically to 4.0 mmol/L. Based on the patient's hypertriglyceridemia, pancreatitis secondary to a primary dyslipidemia was considered most likely. Subsequent lipoprotein electrophoresis demonstrated the presence of chylomicrons, increased very-low-density lipoproteins (VLDL), and decreased high-density lipoprotein.FIGURE 1: Lipemic plasma on admission.A diagnosis of chylomicronemia was made, most likely because of LPL deficiency. Further evaluation for LPL deficiency included LPL gene sequencing and lipid profiles from the patient, her parents, and sibling. The patient's LPL coding region and intron/exon boundaries were sequenced. She was found to be a compound heterozygote for 2 novel LPL mutations. The first was designated c.88 + 2insT and the second was designated p.P214S (see detailed description below). The genogram is presented in Fig. 2.FIGURE 2: Family tree with genotype and phenotype findings.Management of our patient has been focussed on preventing extreme elevations of triglyceride and secondary pancreatitis. A low-fat diet (<10% of total energy) and fat substitution with medium-chain triglycerides have been initiated. Monitoring of her growth parameters and lipid profile on this diet is ongoing. At 12-month follow-up, she remains asymptomatic despite plasma triglyceride concentration varying between 4.0 and 13.0 mmol/L. Her weight and height have been tracking on the 25th percentile. DISCUSSION LPL is the enzyme that acts to hydrolyse triglycerides within chylomicrons and VLDL. Defective LPL activity leads to hypertriglyceridemia as a result of accumulation of chylomicrons and VLDL in the plasma. LPL deficiency is a rare autosomal recessive condition with an estimated prevalence of 1:1,000,000 people (2). Despite a LPL gene mutation carrier rate of 1:35 people, the prevalence is less common than expected, indicating a low penetrance. LPL deficiency usually presents in infancy or early childhood with recurrent episodes of abdominal pain and pancreatitis that settle rapidly on cessation of fat intake. Hepatosplenomegaly, lipemia retinalis, and eruptive xanthomas are other signs of untreated LPL deficiency. Often the initial clue to the diagnosis is lipemic plasma, as observed in our patient. The pathogenesis of pancreatitis in LPL deficiency is not fully understood. Animal models suggest that the chylomicrons are large lipoproteins that marginate in the capillaries and block contact between the erythrocytes and epithelium, resulting in ischemia and subsequent cell damage (3). Pancreatic enzyme release ensues and the combination of a lipemic state and premature pancreatic lipase release combines to release free fatty acids to further damage pancreatic cells by inducing cytokine release and a proinflammatory state. LPL deficiency is caused by mutations on chromosome 8p22. About two thirds of the known LPL mutations are missense mutations in exons 5 and 6 (4). The best-described LPL genetic defects include homozygosity for G188E (resulting in complete absence of LPL activity) and P207L (results in catalytically defective LPL production). Our patient's LPL coding region and intron/exon boundaries were sequenced. She was found to be a compound heterozygote for 2 novel LPL mutations. The first, designated c.88+2insT, is a “T” insertion at the second base of intron 1. The second, designated c.721C>T (p.P214S), is a “C” to “T” substitution in exon 5, predicted to change amino acid Pro214 to Ser (P214S) in the LPL protein product. The mutation c.88+2insT occurs in the intron 1 splice donor site. Based on a splice site prediction algorithm (Splice Site Prediction by Neural Network, http://www.fruitfly.org/seq_tools/splice.html), this mutation would disrupt the intron 1 splice donor site. The actual effect that this mutation would have on LPL mRNA splicing and hence the LPL protein is unknown. However, mutation of G-to-C at position +1 of intron 1, associated with LPL deficiency, was shown to severely reduce the production of normal mRNA transcript to levels detectable only after in vitro amplification, and no cryptic splice sites were utilised (5). The novel missense mutation in exon 5 is predicted to change amino acid Pro214 to Ser (P214S) in the LPL protein product. LPL exon 5 shows strong homology to hepatic lipase and pancreatic lipase, and Pro214 and surrounding residues are completely conserved across species. It has been suggested that mutations occurring in this region affect protein folding and stability (6). In addition, a nearby mutation also involving a proline residue, P207L, causes LPL deficiency (7), and was present in postheparin plasma mainly as a denatured monomer, suggesting that the mutant LPL is unable to achieve or maintain native dimer conformation (8). Present treatment strategy for LPL-deficient patients is to restrict fat intake to <15% of total energy intake to prevent hypertriglyceridemia (9). Medium-chain triglycerides are the preferred fat source because the absorption is directly into the portal vein without being incorporated into chylomicrons. Safety concerns surrounding this extremely low-fat diet on growth and other nutrient deficiencies are genuine, and low iron and calcium levels have been found in the medium-term follow-up of these patients (10). Avoidance of agents known to increase triglyceride levels such as alcohol, steroids, and estrogens is also recommended. Current lipid-lowering agents are not useful in this condition because of a lack of sufficient triglyceride-lowering effect. Fat-soluble vitamin supplementation, antioxidant therapy, plasmapheresis, and surgical management (modified Scopinaro's biliopancreatic diversion) are other treatment options used in LPL deficiency (9). CONCLUSIONS LPL deficiency is a rare genetic disorder that can result in acute pancreatitis in infants and young children. Clinical acumen by both the clinician and pathologist is imperative to facilitate the diagnosis. This is emphasised by the rapid clearance of the chylomicronemia in our patient overnight, highlighting the importance of measuring pancreatic serum enzymes and serum triglyceride in infants and young children with acute pancreatitis or “obscure recurrent abdominal pain” at the time of presentation. Although the full spectrum of genetic defects associated with LPL deficiency has yet to be established, the discovery of these new defects augments the genetic counselling that can be offered to the patients and their families.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2010) conducted a case report in Acute pancreatitis and lipemia due to lipoprotein lipase deficiency (n=1). Low-fat diet and medium-chain triglycerides was evaluated on Prevention of extreme elevations of triglyceride and secondary pancreatitis. A 2-year-old girl with acute pancreatitis and lipemia was found to be a compound heterozygote for two novel lipoprotein lipase mutations and remained asymptomatic on a low-fat diet at 12 months.
Synapse has enriched 10 related papers. Consider them for comparative context: